Lilly buys Scorpion Therapeutics

There is so much talk about Eli Lilly and their exciting weight-loss drugs that we often forget about all the other things happening under the hood. Last week they announced a $2.5 billion cash purchase of Scorpion Therapeutics.

Scorpion Therapeutics has an experimental oral therapy in trials to treat breast cancer. Eli Lilly already has a strong cancer-drug pipeline and the two teams will working closely to get the drug over the line (FDA approval).

Building sufficient manufacturing capacity for weight loss drug production is Eli Lilly's main task, but that will not distract them from developing the rest of their business. The cancer division is still front and centre.